Active Protocols at the Clinic
Our team has rigorous guidelines in place to protect the well-being and safety of clinical trial participants, who are, of course, always fully aware of their participation. This research is carried out in collaboration with Greek and international academic and research institutions and usually results in publication of research papers in peer review journals.
CA209-651: An Open Label, Randomized, Two Arm Phase III Study of Nivolumab in Combination with Ipilimumab versus Extreme Study Regimen (Cetuximab + Cisplatin/Carboplatin + Fluorouracil) as First Line Therapy in Recurrent or Metastatic cancer of the Head and Neck.
RAD1901-308, “ELACESTRANT MONOTHERAPY VS. STANDARD OF CARE FOR THE TREATMENT OF PATIENTS WITH ER+/HER2- ADVANCED BREAST CANCER FOLLOWING CDK4/6 INHIBITOR THERAPY: A PHASE 3 RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED, MULTICENTER TRIAL (EMERALD)”